Thank you for visiting the Collaborative Research Laboratory website!
The Collaborative Research Laboratory was inaugurated in June 2015 to support research activities conducted at St. Luke’s International University and its affiliated hospital. Our research involves clinical trials, innovative medical research, joint research with academia and/or corporate bodies, and trials that have been contracted out for conduct at St. Luke’s International Hospital, but this laboratory also supports all research conducted at St. Luke’s International Hospital and St. Luke’s International University, including research projects of faculty, other staff and students, as well as clinical research born out of the need to find scientific solutions to practical clinical issues encountered in daily practice.
With the globalization of economic activities and information, the medical world is also undergoing increasing levels of globalization. Especially with the rapid economic progress presently seen in neighboring Asian countries, medical services and care have also reached competitively high levels. People now demand the best medical care available, and crossing borders to receive these services, so-called medical tourism, has become a reality. It is our mission to provide the latest advances in medical care based on the latest research to adequately respond to the expectations of all who visit St. Luke’s International Hospital, and to thus fulfill the hospital’s function as a high-quality medical and research institution.
In April 2014, St. Luke’s International Hospital was integrated into St. Luke’s International University, and the associated organizational reforms have served as new motivation on our path of continually aiming at superior quality in research and medicine. With the opening of the Center for Clinical Epidemiology in March 2016, our quest has received new momentum.
The Collaborative Research Laboratory is positioned at the frontline of medical services at St. Luke’s International University and Hospital, and is the heart of all associated research activities, taking an active lead as we proceed with collaborative research, both between different parts of our own system as well as with other medical and research institutions and business corporations, both in Japan and elsewhere.
Thank you so much for your support.
To assure the superior quality of the analytical processes we perform, we have adopted a Quality Management System (QMS) at the Collaborative Research Laboratory. We have prepared and run a quality management program of all equipment used for the measurement of clinical specimens besides the manufacturers’ maintenance programs covered by the guarantees to assure the quality of all analyses. Concerning measurements and other analyses that have not been standardized, we actively participate in proficiency programs initiated by the various academic societies, to continuously secure objective evaluation.
We have also introduced our own specimen management system (SACCESS) that governs the details of all processes from receipt of specimens, through measurement and analysis to storage. The creation of this system was contracted out to an IT company to fit the needs of St. Luke’s International Hospital and this Collaborative Research Laboratory, and now assures that all specimens are automatically tracked by a log system from arrival, through the various processes of measurement and analysis to storage. It also features the use of barcodes for all elements of management. This systems prevents the mix-up of specimens, and assures the traceability of analyses, while simultaneously providing the best protection of personal information.
An automatic alarm system sends temperature and error messages to researchers’ mobile phones in case of any defects with freezers, refrigerators, culturing equipment, etc., that may affect the quality of specimens as an approach to assure maximum safety of specimens.
We are equipped to perform immunological analyses (multi-color flow cytometry, cell sorting based on flow cytometry, and the measurement of cytokines and antibodies), gene and protein as well as other molecular biology analyses (PCR, Real Time PCR, sequencing, ELISA, MSD, Western Blot, etc.), and various cell biological analyses are also possible.
Based on such high-quality analytical analyses, St. Luke’s International Hospital and the Collaborative Research Laboratory sustains collaborative research between different clinical and other departments of St. Luke’s International Hospital, and actively participate in collaborative research with other medical and research institutes in Japan and abroad as well as corporate business partners. For the details of the research we are involved in, please see the section on “Research Activities.”
Until the Center for Clinical Epidemiology was opened on the 7th floor in March 2016, it had operated in an adjacent building.
To be able to perform research involving cell biology and molecular biology techniques, the following equipment are installed:
Multi-color flow cytometry, cell sorter, ERISPOT analysis equipment, etc.
Microplate analyzer, MSD Meso Scale analyzer, multiple biomolecular concentration measuring devices, etc.
Gas chromatograph mass spectrometer
Sequencer, real-time PCR, thermal cycler, etc.
3 Clean benches, 3 biohazard measure cabinets, 4 CO2 incubators, automatic cell counters, etc.
Inverted confocal laser microscopes, inverted fluorescence microscopes, inverted microscopes, stereoscopic microscopes, cooled digital CCD camera imaging apparatuses, etc.
Lumino image analyzer, gel imaging devices, etc.
Ultra-centrifuges, refrigerated centrifuges, desktop multi-book rack centrifuge, small high-speed refrigerated centrifuge, etc.
3 Ultra-low (-80℃) temperature storage freezers, 3 cold storage (-20℃) freezers, 1 liquid nitrogen storage freezer, 4 storage refrigerators (4℃), etc.
Graduated with a medical doctoral degree (PhD) from the Graduate School of Tokushima University in 1992.
After having served as senior researcher at the Drug Efficacy Study Division of the National Cancer Center Research Institute in Japan, visiting professor at the Immunotherapy Center, University of Alabama at Birmingham, internist and senior clinical researcher at the National Hospital Organization Shikoku Cancer Center, and chief of staff at the National Cancer Center Hospital, he has been employed at St. Luke’s International Hospital, since November 2014 as Director of Immunotherapy and Cell Therapy Department and since June 2015 also as Unit Director of the Collaborative Research Laboratory.
He specializes in so-called translational research, including cancer immunotherapy (vaccine therapy, cell immunotherapy, and antibody therapy), and the clinical development of gene therapy.
Medical doctorate (PhD) Left Nagoya University Graduate School in 2006 after completion Served as assistant professor at the Faculty of Pharmaceutical Sciences, Hokuriku University; global COE researcher at The Institute of Medical Science, The University of Tokyo; and chief researcher at the Department of Medical Innovation, St. Luke’s International Medical Center, before taking his present position.
I wish to contribute to the advancement of research rooted in clinical practice based on the physical phenomena of neuroglycan science and epigenetics, with special emphasis on the extracellular matrix and its degradation enzymes.
Graduated from the Faculty of medicine, Mie University in 2004
Medical doctorate (PhD) Left Mie University Graduate School in 2016 after completion
After having served as Staff Physician in the Department of Hematology and Oncology at Mie University Hospital, and as resident and research resident at the Divisions of Hematological Malignancy and Stem Cell Transplantation at the National Cancer Center Research Institute of Japan, he was appointed at the Department of Immunotherapy and Cell Therapy, St. Luke’s International Hospital as adjunct delegated physician since April 2015, and also at the Collaborative Research Laboratory since June of the same year. He specializes in the treatment of hematopoietic tissue malignancies, clinical cancer immunotherapy and translational research. He is specifically presently performing research on the “development of middle molecules for cancer immunotherapy”, and performs screening and functional analysis of proteins used by human immune cells extracted from the artificial protein library of middle molecules (1~8kDa) as a joint project with public institutions. He is also busy with an “immune monitoring study,” that involves the immunological analysis of the peripheral blood of patients undergoing chemotherapy and immunotherapy.
UYAMA Shizuka: Clinical laboratory technologist
SHINOHARA Tsukasa: Research assistant
SATO Yui: Research assistant
KATAKURA Kanae: Research assistant
OKAZAKI Miki (Assitant)